Purpose of Study:To evaluate the effect of macitentan 75 mg versus placebo on exercise capacity at Week 28 in participants with chronic thromboembolic pulmonary hypertension (CTEPH).
July 7, 2020 - May 14, 2024
Type of Study:
Actelion Pharmaceuticals Ltd*
Sponsors:Janssen Pharmaceutical Company of Johnson & Johnson